magrolimab + daratumumab

Magrolimab + daratumumab is an investigational combination therapy composed of two monoclonal antibodies with complementary mechanisms targeting relapsed/refractory multiple myeloma. **Magrolimab** is a monoclonal antibody directed against CD47, a protein overexpressed on tumor cells that acts as a "do not eat me" signal to inhibit phagocytosis. Blockade of CD47 by magrolimab activates macrophages, promoting elimination of myeloma cells. **Daratumumab** is a monoclonal antibody targeting CD38, a glycoprotein highly expressed on myeloma cells, inducing cell death through antibody-dependent cellular phagocytosis, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and functional immune modulation. Preclinical and clinical studies suggest synergistic antitumor activity when combining magrolimab with anti-CD38 therapy. This combination is currently being evaluated in phase 2 clinical trials for safety and efficacy in multiple myeloma patients who have relapsed after previous treatments[1][3][5].

Other names

magrolimab + daratumumab